Showing 1 - 10 of 560
Persistent link: https://www.econbiz.de/10009616664
Persistent link: https://www.econbiz.de/10011294610
Precision medicines inherently fragment treatment populations, generating small-population markets, creating high-priced "niche busters" rather than broadly prescribed "blockbusters". It is plausible to expect that small markets will attract limited entry in which a small number of...
Persistent link: https://www.econbiz.de/10012943199
The economics of stratified medicine depend critically on setting the cut-off score of the companion diagnostic (CDx). This action integrates scientific, clinical, ethical and commercial considerations, and simultaneously determines the value of the stratified medicine to developers, providers,...
Persistent link: https://www.econbiz.de/10013021484
Persistent link: https://www.econbiz.de/10012020069
Persistent link: https://www.econbiz.de/10011772984
Precision medicines inherently fragment treatment populations, generating small-population markets, creating high-priced "niche busters" rather than broadly prescribed "blockbusters". It is plausible to expect that small markets will attract limited entry in which a small number of...
Persistent link: https://www.econbiz.de/10012453693
The economics of stratified medicine depend critically on setting the cut-off score of the companion diagnostic (CDx). This action integrates scientific, clinical, ethical and commercial considerations, and simultaneously determines the value of the stratified medicine to developers, providers,...
Persistent link: https://www.econbiz.de/10012457434
Persistent link: https://www.econbiz.de/10010030048
Much has been written about the seemingly less formal, more agile biotechnology industry and its extensive interactions with academia and startups, as well as its distinct scientific, manufacturing and regulatory profile. Employing a data base encompassing all 96 biologics and 212 small...
Persistent link: https://www.econbiz.de/10013094711